Head of Strategy and Innovation, ReadyTech
Stories naming Dr Chris Smith. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile tracing Sara Prickett's path from UK labs to co-founding Aravax, the peanut-allergy biotech Brandon Capital backed, as its Phase II trial nears readout in mid-2026.
A profile of Brandon Capital partner Chris Smith, tracing his path from immunology research and a Cambridge postdoc into biotech investing, with resilience lessons drawn from equestrian sport and companies Aravax and ENA Respiratory.
A profile of ENA Respiratory traces its INNA-051 immune-boosting nasal spray from an accidental lab finding to Phase 2 trials, noting AUD 49 million in funding, a US Defence contract and Flu Lab investment.
SaaS vendor ReadyTech has officially opened a Tasmanian Centre of Excellence to build local tech skills, with planned training partnerships with the University of Tasmania and TasTAFE as it works toward doubling its workforce.
Biotech Aravax has received a US$20 million Series B commitment from Brandon Capital and Tenmile to advance its peanut allergy therapy PVX108 into Phase 2 trials.
Also Brandon Capital portfolio·Startup Daily·Startup News (WA)·Techboard·Startup Daily
Aravax has begun its Series B with a US$20 million investment from Brandon Capital and Tenmile, funding Phase 2 trials of its peanut allergy immunotherapy PVX108 while it seeks further capital.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Forbes Australia·Techboard·Business News Australia